Effects of atomoxetine on growth after 2-year treatment among pediatric patients with attention-deficit/hyperactivity disorder

Pediatrics

Volumn 116, Issue 1, 2005, Pages

  Spencer, Thomas J ^a   Newcorn, Jeffrey H ^b   Kratochvil, Christopher J ^c   Ruff, Dustin ^d   Michelson, David ^a,e   Biederman, Joseph ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d ELI LILLY AND COMPANY   (United States)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adolescents; Atomoxetine; Attention deficit hyperactivity disorder; Children; Growth

Indexed keywords

ATOMOXETINE; PROPYLAMINE;

ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; BODY HEIGHT; BODY MASS; BODY WEIGHT; CHILD; CHILD GROWTH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DOSE RESPONSE; DRUG EFFICACY; DRUG EXPOSURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PRIORITY JOURNAL; SYSTEMATIC REVIEW; TREATMENT DURATION; UNITED STATES; DRUG EFFECT; GROWTH;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BODY HEIGHT; CHILD; GROWTH; HUMANS; PROPYLAMINES;

EID: 33644626937     PISSN: 00314005     EISSN: 00314005     Source Type: Journal    
DOI: 10.1542/peds.2004-0624     Document Type: Article

References (24)

1. MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 1999;56:1073-1086
2. American Academy of Pediatrics. Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics. 2001;108:1033-1044
3. Biederman J, Faraone SV, Monuteaux MC, Plunkett EA, Gifford J, Spencer T. Growth deficits and attention-deficit/hyperactivity disorder revisited: impact of gender, development, and treatment. Pediatrics. 2003;111:1-6
4. Lisska MC, Rivkees SA. Daily methylphenidate use slows the growth of children: a community based study. J Pediatr Endocrinol Metab. 2003;16:711-718
5. Poulton A, Cowell CT. Slowing of growth in height and weight on stimulants: a characteristic pattern. J Paediatr Child Health. 2003;39:180-185
6. Spencer TJ, Biederman J, Harding M, O'Donnell D, Faraone SV, Wilens TE. Growth deficits in ADHD children revisited: evidence for disorder-associated growth delays? J Am Acad Child Adolesc Psychiatry. 1996;35:1460-1469
7. Spencer T, Biederman J, Wilens T. Growth deficits in children with attention deficit hyperactivity disorder. Pediatrics. 1998;102:501-506
8. Sund AM, Zeiner P. Does extended medication with amphetamine or methylphenidate reduce growth in hyperactive children? Nord J Psychiatry. 2002;56:53-57
9. MTA Cooperative Group. National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: changes in effectiveness and growth after the end of treatment. Pediatrics. 2004;113:762-769
10. Swanson J, Elliott G, Greenhill L, Newcorn J, Jensen P. 24-month stimulant effects on growth in MTA follow-up. Presented at the 50th Annual Meeting of the American Academy of Child and Adolescent Psychiatry; October 14-19, 2003; Miami, FL
11. Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics. 2001;108(5). Available at: www.pediatrics.org/cgi/content/full/108/5/e83
12. Michelson D, Buitelaar JK, Danckaerts M, et al. Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry. 2004;43:896-904
13. Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry. 2002;159:1896-1901
14. Kelsey DK, Sumner CR, Casat CD, et al. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics. 2004;114(1). Available at: www.pediatrics.org/cgi/content/ full/114/1/e1
15. Kaufman J, Birmaher B, Brent D, Rao U, Ryan N. Kiddie-SADS-Present and Lifetime Version (K-SADS-PL): Version 1.0 of October 1996 Edition. Pittsburgh, PA: University of Pittsburgh Press; 1996
16. World Medical Association. Declaration of Helsinki: Recommendations Guiding Medical Doctors in Biomedical Research Involving Human Subjects. Ferney-Voltaire, France: World Medical Association; 2000
17. Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, et al. CDC growth charts: United States. Adv Data. 2000;(314):1-27
18. Spencer TJ. Treatment for ADHD with OROS methylphenidate: long-term effect on growth. Presented at the 156th Annual Meeting of the American Psychiatric Association; May 21, 2003; San Francisco, CA
19. Biederman J, Faraone S, Spencer TJ. Extended release mixed amphetamine salts in ADHD: growth parameter analysis. Presented at the 156th Annual Meeting of the American Psychiatric Association; May 17-22, 2003; San Francisco, CA
20. Tanner JM, Davies PS. Clinical longitudinal standards for height and height velocity for North American children. J Pediatr. 1985;107:317-329
21. Kaplowitz PB, Jennings S. Enhancement of linear growth and weight gain by cyproheptadine in children with hypopituitarism receiving growth hormone therapy. J Pediatr. 1987;110:140-143
22. al Damluji S. Adrenergic control of the secretion of anterior pituitary hormones. Baillieres Clin Endocrinol Metab. 1993;7:355-392
23. Laakmann G, Schoen HW, Blaschke D, Wittmann M. Dose-dependent growth hormone, prolactin and cortisol stimulation after i.v. administration of desimipramine in human subjects. Psychoneuroendocrinology. 1985;10:83-93
24. Lovinger R, Holland J, Kaplan S, et al. Pharmacological evidence for stimulation of growth hormone secretion by a central noradrenergic system in dogs. Neuroscience. 1976;1:443-450